Sunbelt Securities Inc. Acquires 101 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Sunbelt Securities Inc. increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 24.5% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 514 shares of the company’s stock after acquiring an additional 101 shares during the quarter. Sunbelt Securities Inc.’s holdings in Medpace were worth $208,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. LPL Financial LLC boosted its holdings in Medpace by 115.3% in the third quarter. LPL Financial LLC now owns 23,116 shares of the company’s stock worth $5,600,000 after acquiring an additional 12,380 shares in the last quarter. Stifel Financial Corp lifted its holdings in shares of Medpace by 58.6% in the 3rd quarter. Stifel Financial Corp now owns 24,254 shares of the company’s stock worth $5,873,000 after purchasing an additional 8,965 shares in the last quarter. Northern Trust Corp grew its position in Medpace by 4.0% in the 3rd quarter. Northern Trust Corp now owns 241,202 shares of the company’s stock valued at $58,402,000 after purchasing an additional 9,192 shares during the period. Trexquant Investment LP raised its holdings in Medpace by 283.1% during the third quarter. Trexquant Investment LP now owns 6,410 shares of the company’s stock worth $1,552,000 after buying an additional 4,737 shares during the last quarter. Finally, Treasurer of the State of North Carolina raised its holdings in Medpace by 0.5% during the third quarter. Treasurer of the State of North Carolina now owns 10,230 shares of the company’s stock worth $2,477,000 after buying an additional 50 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $411.85 on Friday. The company has a market capitalization of $12.76 billion, a P/E ratio of 41.98, a price-to-earnings-growth ratio of 2.01 and a beta of 1.39. The company’s 50-day moving average is $397.13 and its 200 day moving average is $366.98. Medpace Holdings, Inc. has a fifty-two week low of $227.21 and a fifty-two week high of $437.39.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, beating analysts’ consensus estimates of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The firm had revenue of $511.00 million for the quarter, compared to analysts’ expectations of $512.39 million. During the same period in the previous year, the company earned $2.27 earnings per share. The company’s quarterly revenue was up 17.7% on a year-over-year basis. As a group, research analysts predict that Medpace Holdings, Inc. will post 11.29 earnings per share for the current year.

Insider Buying and Selling at Medpace

In other Medpace news, CEO August J. Troendle sold 4,782 shares of the business’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $400.58, for a total value of $1,915,573.56. Following the sale, the chief executive officer now directly owns 716,197 shares in the company, valued at $286,894,194.26. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO August J. Troendle sold 4,782 shares of Medpace stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $400.58, for a total value of $1,915,573.56. Following the completion of the transaction, the chief executive officer now owns 716,197 shares in the company, valued at $286,894,194.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO August J. Troendle sold 3,987 shares of the company’s stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $395.22, for a total transaction of $1,575,742.14. Following the sale, the chief executive officer now owns 660,351 shares in the company, valued at $260,983,922.22. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,621 shares of company stock valued at $11,816,852. Company insiders own 20.30% of the company’s stock.

Wall Street Analysts Forecast Growth

MEDP has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft began coverage on shares of Medpace in a report on Monday, March 18th. They set a “hold” rating and a $395.00 price objective for the company. Guggenheim lifted their target price on Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Robert W. Baird increased their price target on Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and raised their price objective for the company from $340.00 to $450.00 in a research note on Tuesday, April 23rd. Finally, Mizuho assumed coverage on shares of Medpace in a research note on Tuesday, May 28th. They issued a “buy” rating and a $435.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Medpace has a consensus rating of “Moderate Buy” and a consensus target price of $443.14.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.